$86.03-1.82 (-2.08%)
Corteva, Inc.
Corteva, Inc. in the Basic Materials sector is trading at $86.03 with a market capitalization of $51.2B. Wall Street consensus targets $92.10 (20 analysts), implying a +7.0% move over the next 12 months. The stock is currently near its 52-week high of $90.97, remaining 11.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $4.91B↑ | $3.91B↑ | $2.62B↓ | $6.46B |
| Gross Profit | — | $2.53B↑ | $1.66B↑ | $974.00M↓ | $3.52B |
| Operating Income | — | $1.16B↑ | $242.00M↑ | -$270.00M↓ | $1.83B |
| Net Income | — | $720.00M↑ | -$552.00M↓ | -$320.00M↓ | $1.31B |
Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait techno...

AVO expects record Peru avocado output in fiscal 2026, supporting stronger margins and a fourth-quarter farming contribution.

Corteva Chief Executive Chuck Magro says the company’s soon-to-be spun-off seed business, Vylor, could expand beyond corn and soybeans and into fruits and vegetables, aided by gene-editing advancements.

ADM (ADM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Since the advent of Roundup Ready crops designed to withstand potent weedkillers, seeds and sprays have been entwined in the agriculture industry. Chuck Magro, CEO of Corteva, wants to undo that: Next month, his $55 billion company will split, creating separate businesses focusing on seeds and pesticides.

DOLE vs. CTVA: Which Stock Is the Better Value Option?
Academic risk and quality models computed from CTVA's own filings and price history, not from analyst opinion.
Strong on 7 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 26.9% reading.
Fama-French 5-factor market beta. The five factors explain 15% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.